Oct 16, 2026 12:00PM
Oct 16, 2026 12:00PM
Sep 10, 2026 02:12PM
Sep 9, 2026 12:25PM
Sep 9, 2026 11:55AM
Sep 9, 2026 07:07AM
Aug 19, 2026 04:05PM Longeveron names Nirav Jhaveri as CFO
Aug 19, 2026 04:05PM
Aug 6, 2026 07:00AM
Aug 3, 2026 07:00AM
Aug 3, 2026 07:00AM
Jul 9, 2026 07:02AM
Jul 9, 2026 07:00AM
Jul 6, 2026 12:06PM BTIG on Opus Genetics (IRD): 'the path from here to BLA submission seems clear'
Jul 6, 2026 12:05PM
Jul 6, 2026 07:01AM
Jul 6, 2026 07:00AM
Jun 23, 2026 06:40AM
Jun 17, 2026 04:19AM
May 12, 2026 07:00AM
May 5, 2026 04:21AM Opus Genetics (IRD) Reiterated at Market Outperform by Citizens
May 4, 2026 04:30PM
May 4, 2026 04:30PM
May 4, 2026 10:14AM
Apr 10, 2026 06:59AM
Mar 10, 2026 07:00AM
Feb 25, 2026 06:59AM
Feb 25, 2026 06:59AM Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Jan 20, 2026 05:06AM
Jan 8, 2026 07:07AM
Jan 8, 2026 07:00AM
Nov 12, 2025 07:00AM
Nov 6, 2025 07:03AM
Nov 6, 2025 07:01AM
Nov 6, 2025 07:00AM Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease
Nov 6, 2025 07:00AM
Oct 1, 2025 06:55AM
Sep 30, 2025 07:00AM
Sep 30, 2025 07:00AM
Sep 4, 2025 08:00AM
Sep 4, 2025 08:00AM
Aug 18, 2025 08:01AM Opus Genetics receives FDA clearance for BEST1 gene therapy trial
Aug 18, 2025 08:00AM
Aug 13, 2025 04:30PM
Aug 5, 2025 08:00AM
Jul 23, 2025 08:00AM
Jul 3, 2025 04:30PM
Jun 26, 2025 06:56AM
Jun 26, 2025 06:55AM Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Jun 23, 2025 08:00AM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All